How clinically useful are regulatory trials with new antiepileptic drugs?

Martin J. Brodie
{"title":"How clinically useful are regulatory trials with new antiepileptic drugs?","authors":"Martin J. Brodie","doi":"10.1016/j.epilep.2012.07.002","DOIUrl":null,"url":null,"abstract":"<div><p>Much time, money and effort on behalf of patients, doctors, statisticians, pharmaceutical personnel and regulators are spent in planning and undertaking clinical trial programmes that result in antiepileptic drugs reaching the marketplace and thereafter becoming available for treating people with epilepsy in everyday clinical practice. Rather unusually, both the American and European Authorities require separate trial programmes to licence each drug for their adjunctive and monotherapy use. These studies also often contribute to clinical guideline development. This short paper discusses the design of these trials and their clinical value to the clinician.</p></div>","PeriodicalId":100487,"journal":{"name":"Epileptology","volume":"1 1","pages":"Pages 21-24"},"PeriodicalIF":0.0000,"publicationDate":"2013-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.epilep.2012.07.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epileptology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212822012000038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Much time, money and effort on behalf of patients, doctors, statisticians, pharmaceutical personnel and regulators are spent in planning and undertaking clinical trial programmes that result in antiepileptic drugs reaching the marketplace and thereafter becoming available for treating people with epilepsy in everyday clinical practice. Rather unusually, both the American and European Authorities require separate trial programmes to licence each drug for their adjunctive and monotherapy use. These studies also often contribute to clinical guideline development. This short paper discusses the design of these trials and their clinical value to the clinician.

新型抗癫痫药物的监管试验在临床上有多有用?
患者、医生、统计学家、制药人员和监管机构花费了大量时间、金钱和精力来规划和实施临床试验计划,使抗癫痫药物进入市场,然后在日常临床实践中用于治疗癫痫患者。非常不寻常的是,美国和欧洲当局都要求单独的试验计划来许可每种药物的辅助和单一治疗用途。这些研究通常也有助于临床指南的制定。这篇简短的论文讨论了这些试验的设计及其对临床医生的临床价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信